CytomX Therapeutics Inc (CTMX) concluded trading on Thursday at a closing price of $1.09, with 5.65 million shares of worth about $6.16 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.92% during that period and on May 08, 2025 the price saw a gain of about 13.48%. Currently the company’s common shares owned by public are about 80.10M shares, out of which, 78.64M shares are available for trading.
Stock saw a price change of 43.93% in past 5 days and over the past one month there was a price change of 139.51%. Year-to-date (YTD), CTMX shares are showing a performance of 5.83% which decreased to -75.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $4.20 during that period. The average intraday trading volume for CytomX Therapeutics Inc shares is 2.06 million. The stock is currently trading 46.47% above its 20-day simple moving average (SMA20), while that difference is up 64.46% for SMA50 and it goes to 12.05% higher than SMA200.
CytomX Therapeutics Inc (NASDAQ: CTMX) currently have 80.10M outstanding shares and institutions hold larger chunk of about 57.83% of that.
The stock has a current market capitalization of $87.88M and its 3Y-monthly beta is at 1.15. PE ratio of stock for trailing 12 months is 2.77, while it has posted earnings per share of $0.39 in the same period. It has Quick Ratio of 1.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CTMX, volatility over the week remained 14.40% while standing at 12.40% over the month.
Stock’s fiscal year EPS is expected to drop by -58.68% while it is estimated to decrease by -481.83% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 14, 2025 offering an Overweight rating for the stock and assigned a target price range of between $3.25 and $2.50 to it. Coverage by Piper Sandler stated CytomX Therapeutics Inc (CTMX) stock as an Overweight in their note to investors on May 28, 2024, suggesting a price target of $3.50 for the stock. On May 09, 2024, Wedbush Upgrade their recommendations, while on May 06, 2024, Jefferies Upgrade their ratings for the stock with a price target of $8. Stock get a Neutral rating from JP Morgan on April 22, 2024.
